MRNA Profit Alert: Trader Robot Yields +2.85% in 7 Days
We will analyze the earning results of an AI trading robot accessible at "Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA)" that specializes in trading MRNA during a bearish market trend. The bot's performance has been remarkable, generating a +2.85% gain over the course of the previous week. Additionally, we will examine the latest earnings report for MRNA and discuss potential implications for traders.
AI Trading Robot Performance:
The AI trading robot, accessible at "Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA)," proved its prowess by delivering a noteworthy +2.85% gain while trading MRNA amid a bearish market trend. Such bots, commonly referred to as bot factories, utilize sophisticated algorithms that analyze technical and fundamental indicators to identify lucrative trading opportunities. By harnessing the power of artificial intelligence, these bots can quickly adapt to changing market conditions, allowing them to stay ahead of human traders.
Technical Analysis of MRNA:
On July 12, 2023, MRNA broke above its upper Bollinger Band, a technical indicator commonly used to identify potential overbought conditions. However, this breach could also signal an impending reversal in the stock's price direction. Historically, in 38 out of 45 similar instances where the stock broke above the upper band, the stock subsequently fell afterwards. This data puts the odds of a successful prediction at an impressive 84%.
As the stock moves back below the upper band and toward the middle band, traders may want to consider taking certain actions to capitalize on the potential downtrend. One strategy could be to sell the stock outright, realizing any gains made up until this point. Alternatively, traders could explore put options, which would allow them to profit from a further decline in the stock's price. However, it is essential to exercise caution and conduct thorough research before implementing any trading strategy.
Earnings Report Analysis:
The most recent earnings report for MRNA, released on May 04, showcased a significant earnings surprise. The reported earnings per share (EPS) stood at 18 cents, far surpassing the estimated -175 cents. This unexpected positive performance could have contributed to the stock's recent upward movement. Moreover, the current market capitalization of MRNA stands at an impressive 46.26 billion USD, with 4.06 million shares outstanding.
Summary:
The growing popularity of AI trading robots is reshaping the landscape of financial markets. In this article, we delved into the performance of an AI trading robot accessible at "Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA)," which demonstrated a remarkable +2.85% gain while trading MRNA during a bearish market trend. Additionally, we analyzed technical indicators for MRNA, suggesting a potential downtrend, and the latest earnings report, which showcased significant earnings per share surprise.
MRNA's Indicator enters downward trend
The Aroon Indicator for MRNA entered a downward trend on August 25, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 208 similar instances where the Aroon Indicator formed such a pattern. In of the 208 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 18, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on September 19, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
MRNA moved below its 50-day moving average on September 18, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRNA broke above its upper Bollinger Band on August 22, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Oscillator exited the oversold zone, of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.325) is normal, around the industry mean (22.643). P/E Ratio (35.971) is within average values for comparable stocks, (131.410). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (3.896) is also within normal values, averaging (308.526).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of transformative medicines for patients
Industry Biotechnology
MRNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRNA has been closely correlated with BNTX. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if MRNA jumps, then BNTX could also see price increases.
| Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
|---|---|---|---|---|
| MRNA | 100% | -3.19% | ||
| BNTX - MRNA | 75% Closely correlated | -2.01% | ||
| NVAX - MRNA | 39% Loosely correlated | -3.40% | ||
| VNDA - MRNA | 38% Loosely correlated | +4.21% | ||
| BEAM - MRNA | 36% Loosely correlated | -1.07% | ||
| MDGL - MRNA | 35% Loosely correlated | -1.18% | ||
More | ||||